Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence

References

• Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Eng J Med 2001; 344:1378-88; PMID:11333996; http://dx.doi.org/10.1056/NEJM200105033441807
   PubMed Web of Science ®Google Scholar
• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Meth Mol Biol 2012; 799:1-20; PMID:21993636; http://dx.doi.org/10.1007/978-1-61779-346-2_1
   PubMedGoogle Scholar
• MacNeil JR, Bennett N, Farley MM, Harrison LH, Lynfield R, Nichols M, Petit S, Reingold A, Schaffner W, Thomas A, et al. Epidemiology of infant meningococcal disease in the United States, 2006–2012. Pediatrics 2015; 135:e305-11; PMID:25583921; http://dx.doi.org/10.1542/peds.2014-2035
   PubMed Web of Science ®Google Scholar
• Foster SL, Turner BP, McManus J, Meadows JR, Shelton CM. Meningococcal disease: A brief primer. J Am Pharmacists Assoc 2015; 55:331-4; PMID:26003163; http://dx.doi.org/10.1331/JAPhA.2015.15517
   PubMed Web of Science ®Google Scholar
• Caugant DA, Maiden MC. Meningococcal carriage and disease–population biology and evolution. Vaccine 2009; 27 Suppl 2:B64-70; PMID:19464092; http://dx.doi.org/10.1016/j.vaccine.2009.04.061
   PubMed Web of Science ®Google Scholar
• Pizza M, Rappuoli R. Neisseria meningitidis: pathogenesis and immunity. Curr Opin Microbiol 2015; 23:68-72; PMID:25461575; http://dx.doi.org/10.1016/j.mib.2014.11.006
   PubMed Web of Science ®Google Scholar
• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369:2196-210; PMID:17604802; http://dx.doi.org/10.1016/S0140-6736(07)61016-2
   PubMed Web of Science ®Google Scholar
• Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman JT, Zollinger WD, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerging Infect Dis 2013; 19:566-73; PMID:23628376; http://dx.doi.org/10.3201/eid1904.111799
   PubMed Web of Science ®Google Scholar
• Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global epidemiology of invasive meningococcal disease. Population Health Metrics 2013; 11:17; PMID:24016339; http://dx.doi.org/10.1186/1478-7954-11-17
   PubMed Web of Science ®Google Scholar
• Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century-an update for the clinician. Curr Neurol Neurosci Reports 2015; 15:2; PMID:25637287
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations Reports 2013; 62:1-28
   PubMed Web of Science ®Google Scholar
• Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, Maïnassara HB, Tenebray B, Kairo KK, Giorgini D, Chanteau S. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007; 44:657-63; PMID:17278055; http://dx.doi.org/10.1086/511646
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Dhillon S. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix). Drugs 2012; 72:2407-30; PMID:23231026; http://dx.doi.org/10.2165/11209580-000000000-00000
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27 Suppl 2:B51-63; PMID:19477562; http://dx.doi.org/10.1016/j.vaccine.2009.04.063
   PubMed Web of Science ®Google Scholar
• Hedari CP, Khinkarly RW, Dbaibo GS. Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease. Infect Drug Resistance 2014; 7:85-99; PMID:24729718
   PubMed Web of Science ®Google Scholar
• Miller JM, Mesaros N, Van Der Wielen M, Baine Y. Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience. Adv Preventive Med 2011; 2011:846756; PMID:21991444; http://dx.doi.org/10.4061/2011/846756
   PubMedGoogle Scholar
• Lingappa JR, Al-Rabeah AM, Hajjeh R, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 2003; 9:665-71; PMID:12781005; http://dx.doi.org/10.3201/eid0906.020565
   PubMed Web of Science ®Google Scholar
• Zahlanie YC, Hammadi MM, Ghanem ST, Dbaibo GS. Review of meningococcal vaccines with updates on immunization in adults. Hum Vaccines Immunotherapeutics 2014; 10:995-1007; PMID:24500529; http://dx.doi.org/10.4161/hv.27739
   PubMed Web of Science ®Google Scholar
• Sambo L, Chan M, Davis S, et al. A Vaccine Meets Its Promise: Success in Controlling Epidemic Meningitis in Sub-Saharan Africa. Clin Infect Dis 2015; 61 Suppl 5:S387-8; PMID:26553663; http://dx.doi.org/10.1093/cid/civ490
   PubMedGoogle Scholar
• Aguado MT, Jodar L, Granoff D, Rabinovich R, Ceccarini C, Perkin GW. From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project. Clin Infect Dis 2015; 61 Suppl 5:S391-5; PMID:26553665; http://dx.doi.org/10.1093/cid/civ593
   PubMedGoogle Scholar
• Vannice KS, Keita M, Sow SO, et al. Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali. Clin Infect Dis 2015; 61 Suppl 5:S493-500; PMID:26553680; http://dx.doi.org/10.1093/cid/civ497
   PubMedGoogle Scholar
• Tapia MD, Sow SO, Haidara FC, et al. A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians. Clin Infect Dis 2015; 61 Suppl 5:S507-13; PMID:26553682; http://dx.doi.org/10.1093/cid/civ626
   PubMedGoogle Scholar
• Tapia MD, Findlow H, Idoko OT, et al. Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age. Clin Infect Dis 2015; 61 Suppl 5:S514-20; PMID:26553683; http://dx.doi.org/10.1093/cid/civ672
   PubMedGoogle Scholar
• Diallo A, Sow SO, Idoko OT, et al. Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years. Clin Infect Dis 2015; 61 Suppl 5:S521-30; PMID:26553684; http://dx.doi.org/10.1093/cid/civ518
   PubMedGoogle Scholar
• Lingani C, Bergeron-Caron C, Stuart JM, et al. Meningococcal Meningitis Surveillance in the African Meningitis Belt, 2004-2013. Clin Infect Dis 2015; 61 Suppl 5:S410-5; PMID:26553668; http://dx.doi.org/10.1093/cid/civ597
   PubMed Web of Science ®Google Scholar
• Vogel U, Claus H. Vaccine development against Neisseria meningitidis. Microbial Biotechnol 2011; 4:20-31; PMID:21255369; http://dx.doi.org/10.1111/j.1751-7915.2010.00178.x
   PubMed Web of Science ®Google Scholar
• Hill DJ, Griffiths NJ, Borodina E, Virji M. Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clin Sci 2010; 118:547-64; PMID:20132098; http://dx.doi.org/10.1042/CS20090513
   PubMed Web of Science ®Google Scholar
• Zlotnick GW, Jones TR, Liberator P, et al. The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease. Hum Vaccines Immunotherapeutics 2015; 11:5-13; PMID:25483509; http://dx.doi.org/10.4161/hv.34293
   PubMed Web of Science ®Google Scholar
• Xie O, Pollard AJ, Mueller JE, Norheim G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine 2013; 31:2852-61; PMID:23623866; http://dx.doi.org/10.1016/j.vaccine.2013.04.036
   PubMed Web of Science ®Google Scholar
• Roderick M, Finn A. Advances towards the prevention of meningococcal B disease: a multidimensional story. J Infect 2014; 68 Suppl 1:S76-82; PMID:24139188; http://dx.doi.org/10.1016/j.jinf.2013.09.026
   PubMed Web of Science ®Google Scholar
• Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine 2006; 24:4692-700; PMID:16621189; http://dx.doi.org/10.1016/j.vaccine.2006.03.034
   PubMed Web of Science ®Google Scholar
• Shao PL, Chang LY, Hsieh SM, et al. Safety and immunogenicity of a tetravalent polysaccharide vaccine against meningococcal disease. J Formosan Medical Association = Taiwan yi zhi 2009; 108:539-47; PMID:19586827; http://dx.doi.org/10.1016/S0929-6646(09)60371-5
   PubMed Web of Science ®Google Scholar
• Choudhuri D, Huda T, Theodoratou E, et al. An evaluation of emerging vaccines for childhood meningococcal disease. BMC Public Health 2011; 11 Suppl 3:S29; PMID:21501447; http://dx.doi.org/10.1186/1471-2458-11-S3-S29
   PubMedGoogle Scholar
• Papaevangelou V, Spyridis N. MenACWY-TT vaccine for active immunization against invasive meningococcal disease. Exp Rev Vaccines 2012; 11:523-37; PMID:22827239; http://dx.doi.org/10.1586/erv.12.32
   PubMed Web of Science ®Google Scholar
• Muthukkumar S, Stein KE. Immunization with meningococcal polysaccharide-tetanus toxoid conjugate induces polysaccharide-reactive T cells in mice. Vaccine 2004; 22:1290-9; PMID:15003659; http://dx.doi.org/10.1016/j.vaccine.2003.08.047
   PubMed Web of Science ®Google Scholar
• Strikas RA, Centers for Disease C, Prevention, Advisory Committee on Immunization P, Group ACAIW. Advisory committee on immunization practices recommended immunization schedules for persons aged 0 through 18 years–United States, 2015. MMWR Morbidity Mortality Weekly Report 2015; 64:93-4; PMID:25654610
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Inc. Nimenrix_Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine. Product Monograph GlaxoSmithKline Inc 2015
   Google Scholar
• Ghanem S, Hassan S, Saad R, Dbaibo GS. Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review. Expert opinion on biological therapy 2013; 13:1197-205; PMID:23815506; http://dx.doi.org/10.1517/14712598.2013.812629
   PubMed Web of Science ®Google Scholar
• Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27 Suppl 2:B112-6; http://dx.doi.org/10.1016/j.vaccine.2009.04.065
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine 2005; 23:2222-7; PMID:15755600; http://dx.doi.org/10.1016/j.vaccine.2005.01.051
   PubMed Web of Science ®Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagnostic Lab Immunol 2003; 10:780-6; PMID:12965904
   PubMedGoogle Scholar
• Knuf M, Kieninger-Baum D, Habermehl P, Muttonen P, Maurer H, Vink P, Poolman J, Boutriau D. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010; 28:744-53; PMID:19887137; http://dx.doi.org/10.1016/j.vaccine.2009.10.064
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vacc Immunotherapeutics 2012; 8:1892-903; PMID:23032159; http://dx.doi.org/10.4161/hv.22166
   PubMed Web of Science ®Google Scholar
• Klein NP, Baine Y, Bianco V, Lestrate PR, Naz A, Blatter M, Friedland LR, Miller JM. One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children. Pediatr Infect Dis J 2013; 32:760-7; PMID:23348814; http://dx.doi.org/10.1097/INF.0b013e31828693c5
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. Vaccine 2011; 29:4274-84; PMID:21443965; http://dx.doi.org/10.1016/j.vaccine.2011.03.043
   PubMed Web of Science ®Google Scholar
• Leonardi M, Latiolais T, Sarpong K, Simon M, Twiggs J, Lei P, Rinderknecht S, Blatter M, Bianco V, Baine Y et al., Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy. Vaccine 2015; 33:933-41; PMID:25152325; http://dx.doi.org/10.1016/j.vaccine.2014.08.027
   PubMed Web of Science ®Google Scholar
• Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, Bianco V, Van der Wielen M, Gatchalian S, Miller JM. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J 2011; 30:e56-62; PMID:21278617; http://dx.doi.org/10.1097/INF.0b013e31820e6e02
   PubMed Web of Science ®Google Scholar
• Dbaibo G, Van der Wielen M, Reda M, Medlej F, Tabet C, Boutriau D, Sumbul A, Anis S, Miller JM. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine. Int J Infect Dis 2012; 16:e608-15; PMID:22704725; http://dx.doi.org/10.1016/j.ijid.2012.04.006
   PubMedGoogle Scholar
• Vesikari T, Forsten A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years. Hum Vaccines Immunotherapeutics 2012; 8:1882-91; PMID:23032168; http://dx.doi.org/10.4161/hv.22165
   PubMed Web of Science ®Google Scholar
• Knuf M, Romain O, Kindler K, Walther U, Tran PM, Pankow-Culot H, Fischbach T, Kieninger-Baum D, Bianco V, Baine Y, et al. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study. Eur J Pediatrics 2013; 172:601-12; PMID:23307281; http://dx.doi.org/10.1007/s00431-012-1924-0
   PubMed Web of Science ®Google Scholar
• Halperin SA, Baine Y, Domachowske JB, Aggarwal N, Simon M, Langley JM, McNeil SA, Friedland LR, Bianco V, Baccarini CI, et al. Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age. J Pediatric Infect Dis Society 2014; 3:33-42; PMID:24567843; http://dx.doi.org/10.1093/jpids/pit058
   PubMedGoogle Scholar
• Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009; 27:161-8; PMID:18834910; http://dx.doi.org/10.1016/j.vaccine.2008.08.075
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J 2011; 30:e41-8; PMID:21200360; http://dx.doi.org/10.1097/INF.0b013e3182054ab9
   PubMed Web of Science ®Google Scholar
• Bermal N, Huang LM, Dubey AP, Jain H, Bavdekar A, Lin TY, Bianco V, Baine Y, Miller JM. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccines 2011; 7:239-47; PMID:21343698; http://dx.doi.org/10.4161/hv.7.2.14068
   PubMed Web of Science ®Google Scholar
• Borja-Tabora C, Montalban C, Memish ZA, Van der Wielen M, Bianco V, Boutriau D, Miller J. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis 2013; 13:116; PMID:23510357
   PubMed Web of Science ®Google Scholar
• Berry DS, Lynn F, Lee CH, Frasch CE, Bash MC. Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses. Infect Immunity 2002; 70:3707-13; PMID:12065513; http://dx.doi.org/10.1128/IAI.70.7.3707-3713.2002
   PubMed Web of Science ®Google Scholar
• Lupisan S, Limkittikul K, Sosa N, Chanthavanich P, Bianco V, Baine Y, Van der Wielen M, Miller JM. Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years. Clin Vaccine Immunol 2013; 20:1499-507; PMID:23885033; http://dx.doi.org/10.1128/CVI.00162-13
   PubMed Web of Science ®Google Scholar
• Dbaibo G, Macalalad N, Aplasca-De Los Reyes MR, Dimaano E, Bianco V, Baine Y, Miller J. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study. Hum Vaccines Immunotherapeutics 2012; 8:873-80; PMID:22485050; http://dx.doi.org/10.4161/hv.20211
   PubMed Web of Science ®Google Scholar
• Dbaibo G, El-Ayoubi N, Ghanem S, Hajar F, Bianco V, Miller JM, Mesaros N. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial. Drugs Aging 2013; 30:309-19; PMID:23494214; http://dx.doi.org/10.1007/s40266-013-0065-0
   PubMed Web of Science ®Google Scholar
• Knuf M, Baine Y, Bianco V, Boutriau D, Miller JM. Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children. Hum Vaccines Immunotherapeutics 2012; 8:866-72; PMID:22485049; http://dx.doi.org/10.4161/hv.20229
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Van der Wielen M, Bianco V, Miller JM. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT). Int J Infect Dis 2013; 17:e173-6; PMID:23246368; http://dx.doi.org/10.1016/j.ijid.2012.10.001
   PubMed Web of Science ®Google Scholar
• National Center for I, Respiratory D. General recommendations on immunization — recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations Reports 2011; 60:1-64
   Google Scholar
• Aplasca-De Los Reyes MR, Dimaano E, Macalalad N, Dbaibo G, Bianco V, Baine Y, Miller J. The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. Human Vaccines Immunotherapeutics 2012; 8:881-7; PMID:22485048; http://dx.doi.org/10.4161/hv.20212
   PubMed Web of Science ®Google Scholar
• Van Damme P, Van Herck K. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Expert Rev Vaccines 2004; 3:249-67; PMID:15176942; http://dx.doi.org/10.1586/14760584.3.3.249
   PubMedGoogle Scholar
• Van Damme P, Van der Wielen M. Combining hepatitis A and B vaccination in children and adolescents. Vaccine 2001; 19:2407-12; PMID:11257370; http://dx.doi.org/10.1016/S0264-410X(00)00464-3
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Silfverdal SA, Berglund J, Flodmark CE, West C, Bianco V, Baine Y, Miller JM. A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix((R)) in subjects aged 11-17 years: an open, randomised, controlled trial. Vaccine 2012; 30:774-83; PMID:22107850; http://dx.doi.org/10.1016/j.vaccine.2011.11.051
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Huang LM, Lin TY, Hernandez L, Guerrero ML, Villalobos AL, Van der Wielen M, Moreira M, Fissette L, Borys D, et al. Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial. Pediatr Infect Dis J 2013; 32:62-71; PMID:23076383
   PubMed Web of Science ®Google Scholar
• Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, Fischbach T, Zinke H, Pankow-Culot H, Papaevangelou V, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 2011; 29:4264-73; PMID:21420417; http://dx.doi.org/10.1016/j.vaccine.2011.03.009
   PubMed Web of Science ®Google Scholar
• Leonardi M, Latiolais T, Sarpong K, Simon M, Twiggs J, Lei P, Rinderknecht S, Blatter M, Bianco V, Baine Y, et al. Immunogenicity and reactogenicity of Infanrix when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix and Pediarix. Vaccine 2015; 33:924-32; PMID:25305567; http://dx.doi.org/10.1016/j.vaccine.2014.09.064
   PubMed Web of Science ®Google Scholar
• Guidance Meningococcal: the green book. Public Health England; 2015. Available from https://www.gov.uk/government/publications/meningococcal-the-green-book-chapter-22
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe 2008/2009. Stockholm: ECDC; 2011
   Google Scholar
• European Public Assessment Report–European Medicines Agency. 2012. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002226/WC500127664.pdf
   Google Scholar
• Ative Bacterial Surveillance (ABCs): Emerging Infections Program Network. 2014. Available from http://www.cdc.gov/abcs/reports-findings/survreports/mening14.html
   Google Scholar
• Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Sáfadi MA. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012; 30 Suppl 2:B26-36; PMID:22178525; http://dx.doi.org/10.1016/j.vaccine.2011.12.032
   PubMed Web of Science ®Google Scholar
• Safadi MA, Cintra OA. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurological Res 2010; 32:263-71; PMID:20406604; http://dx.doi.org/10.1179/016164110X12644252260754
   PubMed Web of Science ®Google Scholar
• Al-Mazrou YY, Al-Jeffri MH, Abdalla MN, Elgizouli SA, Mishskas AA. Changes in epidemiological pattern of Meningococcal disease in Saudi Arabia. Does it constitute a new challenge for prevention and control? Saudi medical J 2004; 25:1410-3; PMID:15494812
   PubMed Web of Science ®Google Scholar
• National Institute for Communicable Diseases. Communicable Diseases Surveillance Bulletin 2009; 7(1). Available from http://www.nicd.ac.za/pubs/survbull/2009/CommDisBullMar09.pdf
   Google Scholar
• Li J, Li Y, Shao Z, Shao Z, Li L, Yin Z, Ning G, Xu L, Luo H. Prevalence of meningococcal meningitis in China from 2005 to 2010. Vaccine 2015; 33:1092-7; PMID:25444796; http://dx.doi.org/10.1016/j.vaccine.2014.10.072
   PubMed Web of Science ®Google Scholar
• Takahashi H, Kuroki T, Watanabe Y, Tanaka H, Inouye H, Yamai S, Watanabe H. Characterization of Neisseria meningitidis isolates collected from 1974 to 2003 in Japan by multilocus sequence typing. J Medical Microbiol 2004; 53:657-62; PMID:15184538; http://dx.doi.org/10.1099/jmm.0.45541-0
   PubMed Web of Science ®Google Scholar